Norges Bank Intercept Pharmaceuticals, Inc. Transaction History

Norges Bank

$716 Trillion
Q3 2024

38 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2023	BUY	$13.37 - $17.79 $231,220 - $307,660	17,294 New	17,294 $281,000
Q1 2022 May 09, 2022	SELL	$13.37 - $17.79 $231,220 - $307,660	-17,294 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$14.28 - $19.53 $246,958 - $337,751	17,294 New	17,294 $282,000
Q3 2021 Nov 14, 2022	BUY	$12.99 - $20.47 $224,649 - $354,008	17,294 New	17,294 $257,000
Q3 2021 Nov 05, 2021	SELL	$12.99 - $20.47 $1.66 Million - $2.62 Million	-128,071 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$15.46 - $24.5 $1.98 Million - $3.14 Million	128,071 New	128,071 $2.56 Million
Q2 2021 Aug 10, 2021	SELL	$15.46 - $24.5 $1.53 Million - $2.43 Million	-99,035 Closed	0 $0
Q1 2021 May 09, 2022	BUY	$19.33 - $37.75 $1.91 Million - $3.74 Million	99,035 New	99,035 $2.29 Million
Q1 2021 May 07, 2021	SELL	$19.33 - $37.75 $3.74 Million - $7.31 Million	-193,621 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$24.48 - $42.47 $4.74 Million - $8.22 Million	193,621 New	193,621 $4.78 Million
Q4 2020 Feb 10, 2021	SELL	$24.48 - $42.47 $4.2 Million - $7.29 Million	-171,545 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$39.09 - $53.44 $6.71 Million - $9.17 Million	171,545 New	171,545 $7.11 Million
Q3 2020 Nov 10, 2020	SELL	$39.09 - $53.44 $9.72 Million - $13.3 Million	-248,708 Closed	0 $0
Q2 2020 Aug 13, 2021	BUY	$46.7 - $92.04 $11.6 Million - $22.9 Million	248,708 New	248,708 $11.9 Million
Q2 2020 Aug 07, 2020	SELL	$46.7 - $92.04 $15 Million - $29.5 Million	-320,216 Closed	0 $0
Q1 2020 May 07, 2021	BUY	$48.35 - $118.68 $15.5 Million - $38 Million	320,216 New	320,216 $20.2 Million
Q1 2020 May 08, 2020	SELL	$48.35 - $118.68 $14.6 Million - $35.8 Million	-301,988 Closed	0 $0
Q4 2019 Mar 03, 2020	BUY	$57.36 - $124.1 $17.3 Million - $37.5 Million	301,988 New	301,988 $37.4 Million
Q4 2019 Feb 12, 2020	SELL	$57.36 - $124.1 $17.3 Million - $37.5 Million	-301,988 Closed	0 $0
Q3 2019 Nov 13, 2020	BUY	$58.69 - $80.46 $17.7 Million - $24.3 Million	301,988 New	301,988 $20 Million
Q3 2019 Nov 08, 2019	SELL	$58.69 - $80.46 $17.7 Million - $24.3 Million	-301,988 Closed	0 $0
Q2 2019 Aug 13, 2020	BUY	$77.77 - $120.68 $23.5 Million - $36.4 Million	301,988 New	301,988 $24 Million
Q2 2019 Aug 09, 2019	SELL	$77.77 - $120.68 $21.9 Million - $34 Million	-282,045 Closed	0 $0
Q4 2018 Mar 04, 2019	BUY	$85.79 - $126.46 $24.2 Million - $35.7 Million	282,045 New	282,045 $28.4 Million
Q4 2018 Feb 08, 2019	SELL	$85.79 - $126.46 $24.2 Million - $35.7 Million	-282,045 Closed	0 $0
Q3 2018 Nov 12, 2019	BUY	$88.49 - $127.55 $25 Million - $36 Million	282,045 New	282,045 $35.6 Million
Q3 2018 Nov 09, 2018	SELL	$88.49 - $127.55 $16.6 Million - $23.9 Million	-187,769 Closed	0 $0
Q2 2018 Aug 12, 2019	BUY	$60.0 - $85.67 $11.3 Million - $16.1 Million	187,769 New	187,769 $15.8 Million
Q2 2018 Jul 23, 2018	SELL	$60.0 - $85.67 $2.06 Million - $2.94 Million	-34,265 Closed	0 $0
Q1 2018 May 15, 2019	BUY	$52.72 - $67.25 $1.81 Million - $2.3 Million	34,265 New	34,265 $2.11 Million
Q1 2018 May 09, 2018	SELL	$52.72 - $67.25 $846,946 - $1.08 Million	-16,065 Closed	0 $0
Q4 2017 Mar 05, 2018	BUY	$58.2 - $72.76 $934,983 - $1.17 Million	16,065 New	16,065 $939,000
Q4 2017 Feb 09, 2018	SELL	$58.2 - $72.76 $934,983 - $1.17 Million	-16,065 Closed	0 $0
Q3 2017 Nov 13, 2018	BUY	$57.01 - $118.75 $915,865 - $1.91 Million	16,065 New	16,065 $932,000
Q3 2017 Nov 07, 2017	SELL	$57.01 - $118.75 $316,804 - $659,893	-5,557 Closed	0 $0
Q2 2017 Jul 24, 2018	SELL	N/A	-66,324 Reduced 92.27%	5,557 $673,000
Q1 2017 May 11, 2018	SELL	N/A	-69,486 Reduced 49.15%	71,881 $8.13 Million
Q3 2016 Nov 13, 2017	BUY	N/A	141,367	141,367 $0

Others Institutions Holding ICPT

# of Institutions

Shares Held

1.04M

Call Options Held

30K

Put Options Held

5.9K

View Full List

About INTERCEPT PHARMACEUTICALS, INC.

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

More about ICPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.

Account